Just2Trade, a leading financial company for private investors worldwide, has won the Best Multi-Asset Broker // Asia – 2021 award.
The award was given to Just2Trade during this year's BrokersShow in Taiwan on April 24, 2021 (see https://info.brokersshow.com/en/news/details/663). This year the popular exhibition was held online due to the Covid-19 pandemic, with more than 50,000 visitors. The event was not only a cloud event to facilitate communication between the financial industry platform and investors during the pandemic, but also an investigation and evaluation of the comprehensive strength of major brokers.
Just2Trade is part of a global financial group run by veterans of the modern financial industry, offering services to private investors since 1994. The Group’s companies are authorized and strictly regulated in the EU, US and Russia. Just2Trade has worked with Asian customers since 2011. Currently, the company has over 155,000 customers in 130 countries and is headquartered in Limassol, Cyprus.
The high award for Just2Trade’s operations reflects the Company’s unique services for private investors. Just2Trade’s key product – the MT5 trading platform – provides customers with direct access to 20 major global exchanges and has a truly unique range of financial instruments – over 128,000 trading products, including forex, stocks, bonds, futures, options and cryptocurrency.
Compared to its competitors, Just2Trade not only has a unique basket of tradable instruments but also affords customers a choice of several trading platforms. Aside from MT5, the Company also offers the MT4, CQG and ROX platforms to its customers.
Thanks to its state-of-the-art technological infrastructure, the Company is able to provide its services to customers with rock-bottom fees and maximum liquidity. “Users have high expectations when it comes to service quality, especially for brokers like us with a history of more than 25 years. It is a challenge to meet these expectations” – says Anton Tishenko, Just2Trade’s Asia Business Development Director.